Hosted on MSN11mon
EC approves Bristol Myers Squibb’s Reblozyl for first-line MDS treatment
The trial assessed the efficacy and safety of Reblozyl compared to epoetin alfa, an erythropoiesis-stimulating agent, in treating anaemia due to MDS. It included subjects who needed red blood cell ...
pharmaphorum9d
BMS grabs key approval for Reblozyl in MDS
Reblozyl was found to be superior to standard ESA therapy with Amgen and Johnson & Johnson's Epogen/Procrit (epoetin alfa) at achieving those objectives, with almost 59% of patients on BMS' drug ...
pharmaphorum2d
BMS announces positive Reblozyl phase 3 results for MDS
The COMMANDS study (NCT03682536) - a phase 3 open-label, randomised trial to evaluate the efficacy and safety of Reblozyl versus epoetin alfa - demonstrated high statistical significance and ...
Seeking Alpha20d
JCRRF JCR Pharmaceuticals Co., Ltd.
The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments ...
Targeted Oncology11d
Transfusion Independence Serves as Key End Point for LR-MDS Trials
Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk ...